Baird lowered the firm’s price target on Sage Therapeutics to $13 from $15 and keeps a Neutral rating on the shares. The firm removed SAGE-324 for essential tremor from their model after Sage announced that the phase 2 KINETIC-2 dose-range study of SAGE-324 in essential tremor was not successful.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics, Biogen report results from Phase 2 study of SAGE-324
- Sage Therapeutics price target lowered to $16 from $18 at Mizuho
- Sage Therapeutics price target lowered to $18 from $23 at JPMorgan
- Sage Therapeutics price target lowered to $23 from $28 at JPMorgan
- Biotech Alert: Searches spiking for these stocks today